Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 29Lymphoma, B-Cell 6Lymphoma, Follicular 5Lymphoma, Mantle-Cell 4Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Recurrence 2Hodgkin Disease 2Dendritic Cell Sarcoma, Interdigitating 2Burkitt Lymphoma 1

Interventions

Cyclophosphamide 297Rituximab 272Etoposide 149Filgrastim 142fludarabine phosphate 120Cytarabine 109Vincristine 107Melphalan 102Radiotherapy 101Doxorubicin 97Peripheral Blood Stem Cell Transplantation 93Methotrexate 91fludarabine 86Prednisone 86Busulfan 86Tacrolimus 66Mycophenolic Acid 62Granulocyte Colony-Stimulating Factor 60Antilymphocyte Serum 58Dexamethasone 57Whole-Body Irradiation 55Carmustine 54Bortezomib 45Cyclosporine 44Lenalidomide 41Methylprednisolone 40sargramostim 39Bendamustine Hydrochloride 37ibritumomab tiuxetan 34Ifosfamide 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lymphoma × polatuzumab vedotin × Clear all
NCT07502872 2026-03-31

TPG

Brown University

Phase 2 Not yet recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Recruiting
41 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05410418 2025-12-15

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Washington University School of Medicine

Phase 2 Active not recruiting
34 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡